Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 First-in-human Study of the Safety and Efficacy of IMC-C103C as Single Agent and in Combination With Atezolizumab in HLA-A0201-positive Patients With Advanced MAGE-A4-positive Cancer

Next Previous
Trial Profile

A Phase 1/2 First-in-human Study of the Safety and Efficacy of IMC-C103C as Single Agent and in Combination With Atezolizumab in HLA-A0201-positive Patients With Advanced MAGE-A4-positive Cancer

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 05 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary) ; IMC C103C (Primary)
  • Indications Gastric cancer; Head and neck cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Solid tumours; Squamous cell cancer; Synovial sarcoma; Urogenital cancer
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Immunocore

    • Most Recent Events

    • 29 Jan 2024 Status changed from active, no longer recruiting to discontinued (The Sponsor terminated the study and there is no further enrollment. Endpoints will not beassessed for this trial).
    • 27 Sep 2023 Planned End Date changed from 1 Jul 2025 to 1 Feb 2024.
    • 27 Sep 2023 Status changed from recruiting to active, no longer recruiting.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top